TMP-SMX for MRSA Urinary Tract Infections
For MRSA UTI in adults with normal renal function, use TMP-SMX 1-2 double-strength (DS) tablets (160/800 mg) twice daily for 10-14 days.
Dosing Recommendation
The FDA-approved dosing for urinary tract infections is 1 DS tablet (160 mg TMP/800 mg SMX) or 2 single-strength tablets every 12 hours for 10-14 days 1. This translates to:
- Standard dose: 1 DS tablet (160/800 mg) PO BID
- Higher dose option: 2 DS tablets (320/1600 mg) PO BID
Evidence for Dosing Choice
While the IDSA MRSA guidelines 2 list TMP-SMX as a treatment option for various MRSA infections (including bone/joint infections at 3.5-4.0 mg/kg/dose every 8-12 hours), they do not specifically address MRSA UTI. The guidelines focus primarily on skin/soft tissue infections, bacteremia, pneumonia, and bone/joint infections.
For MRSA skin infections, research shows that higher doses (320/1600 mg BID) achieved similar clinical resolution rates (73%) compared to standard doses (160/800 mg BID, 75% resolution) over 7-15 days 3. This suggests the standard FDA-approved dose is likely adequate for most MRSA infections.
Duration of Treatment
Treat for 10-14 days based on FDA labeling for UTI 1. The 2024 WikiGuidelines consensus 4 notes insufficient evidence to provide clear duration recommendations for TMP-SMX in adult pyelonephritis, but standard UTI treatment durations apply.
Clinical Context
- Simple cystitis: May consider shorter courses (closer to 10 days)
- Complicated UTI or pyelonephritis: Use full 14-day course
- Catheter-associated MRSA UTI: Consider 14 days given complexity
Important Caveats
Renal function adjustment is critical: With creatinine clearance 15-30 mL/min, use half the usual dose; avoid if CrCl <15 mL/min 1.
MRSA UTI is uncommon but serious: MRSA accounts for only 2-10% of UTIs but carries risk of bacteremia, particularly in catheterized or hospitalized patients 5. The isolation of MRSA in urine often precedes life-threatening MRSA bacteremia 6.
Resistance considerations: TMP-SMX resistance in MRSA is variable and particularly high in HIV populations due to Pneumocystis prophylaxis exposure 7. Verify susceptibility before continuing therapy beyond empiric treatment.
Alternative agents if TMP-SMX resistant or contraindicated:
- Vancomycin 15-20 mg/kg IV every 8-12 hours
- Linezolid 600 mg PO/IV BID
- Consider nitrofurantoin for cystitis only (not for pyelonephritis or systemic infection)
Practical Algorithm
- Confirm MRSA susceptibility to TMP-SMX from culture
- Assess renal function and adjust dose accordingly
- Determine infection severity:
- Uncomplicated cystitis → 10 days
- Pyelonephritis or complicated UTI → 14 days
- Start with standard dose (1 DS tablet BID) unless severe infection warrants higher dosing
- Monitor clinical response at 48-72 hours; if no improvement, consider IV therapy
The standard FDA-approved dose is appropriate for most cases, with duration guided by infection complexity rather than pathogen-specific factors.